Matrisomic characterization of HCC to inform individualized patient management
- PMID: 37163234
- PMCID: PMC10527036
- DOI: 10.1097/HEP.0000000000000443
Matrisomic characterization of HCC to inform individualized patient management
Conflict of interest statement
Conflict of interest
YH is shareholder for Alentis Therapeutics and Espervita Therapeutics, advisory for Helio Genomics, Espervita Therapeutics, and Roche Diagnostics.
Figures
Comment on
-
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome.Hepatology. 2023 Sep 1;78(3):741-757. doi: 10.1097/HEP.0000000000000362. Epub 2023 Apr 1. Hepatology. 2023. PMID: 36999534
References
-
- Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet 2022;400:1345–1362. - PubMed
-
- Fernandez-Sanchez ME, Barbier S, Whitehead J, Bealle G, Michel A, Latorre-Ossa H, Rey C, et al. Mechanical induction of the tumorigenic beta-catenin pathway by tumour growth pressure. Nature 2015;523:92–95. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
